TY - JOUR
T1 - Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
AU - Barbui, Tiziano
AU - Thiele, Jürgen
AU - Passamonti, Francesco
AU - Rumi, Elisa
AU - Boveri, Emanuela
AU - Randi, Maria Luigia
AU - Bertozzi, Irene
AU - Marino, Filippo
AU - Vannucchi, Alessandro M.
AU - Pieri, Lisa
AU - Rotunno, Giada
AU - Gisslinger, Heinz
AU - Gisslinger, Bettina
AU - Müllauer, Leonhard
AU - Finazzi, Guido
AU - Carobbio, Alessandra
AU - Gianatti, Andrea
AU - Ruggeri, Marco
AU - Nichele, Ilaria
AU - D'Amore, Emanuele
AU - Rambaldi, Alessandro
AU - Tefferi, Ayalew
PY - 2012/3/8
Y1 - 2012/3/8
N2 - We examined the prevalence and prognostic relevance of bone marrow reticulin fibrosis in 526 patients with World Health Organization-defined polycythemia vera evaluated at the time of initial diagnosis. Seventy-four patients (14%) displayed mostly grade 1 reticulin fibrosis, with only 2 cases showing higher-grade fibrosis. Presenting clinical and laboratory characteristics, including JAK2V617F allele burden, between patients with and without fibrosis were similar for the most part, with the exception of a higher prevalence of palpable splenomegaly in patients with fibrosis (P <.01). Patients with fibrosis were less prone to experience thrombosis during their clinical course (1.1 vs 2.7 per 100 patient-years; P = .03) and more prone to develop post-polycythemia vera myelofibrosis (2.2 vs 0.8 per 100 patient-years; P = .01). There was no significant difference between the 2 groups in terms of overall or leukemia-free survival. The present study clarifies the incidence, degree, and prognostic relevance of bone marrow fibrosis obtained at time of initial diagnosis of polycythemia vera.
AB - We examined the prevalence and prognostic relevance of bone marrow reticulin fibrosis in 526 patients with World Health Organization-defined polycythemia vera evaluated at the time of initial diagnosis. Seventy-four patients (14%) displayed mostly grade 1 reticulin fibrosis, with only 2 cases showing higher-grade fibrosis. Presenting clinical and laboratory characteristics, including JAK2V617F allele burden, between patients with and without fibrosis were similar for the most part, with the exception of a higher prevalence of palpable splenomegaly in patients with fibrosis (P <.01). Patients with fibrosis were less prone to experience thrombosis during their clinical course (1.1 vs 2.7 per 100 patient-years; P = .03) and more prone to develop post-polycythemia vera myelofibrosis (2.2 vs 0.8 per 100 patient-years; P = .01). There was no significant difference between the 2 groups in terms of overall or leukemia-free survival. The present study clarifies the incidence, degree, and prognostic relevance of bone marrow fibrosis obtained at time of initial diagnosis of polycythemia vera.
UR - http://www.scopus.com/inward/record.url?scp=84858062280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858062280&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-11-393819
DO - 10.1182/blood-2011-11-393819
M3 - Article
C2 - 22246040
AN - SCOPUS:84858062280
SN - 0006-4971
VL - 119
SP - 2239
EP - 2241
JO - Blood
JF - Blood
IS - 10
ER -